248 related articles for article (PubMed ID: 8680050)
1. Rescue therapy with mycophenolate mofetil. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Clin Transplant; 1996 Feb; 10(1 Pt 2):131-5. PubMed ID: 8680050
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
Sollinger HW
Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
[TBL] [Abstract][Full Text] [Related]
5. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.
Halloran P; Mathew T; Tomlanovich S; Groth C; Hooftman L; Barker C
Transplantation; 1997 Jan; 63(1):39-47. PubMed ID: 9000658
[TBL] [Abstract][Full Text] [Related]
9. Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients.
Vasquez EM; Sifontis NM; Pollak R; Benedetti E
Clin Transplant; 2001 Aug; 15(4):253-7. PubMed ID: 11683819
[TBL] [Abstract][Full Text] [Related]
10. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
Wiesel M; Carl S
J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus rescue therapy for refractory rejection in renal transplantation.
Hong JC; Kahan BD
Transplantation; 2001 Jun; 71(11):1579-84. PubMed ID: 11435968
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
[TBL] [Abstract][Full Text] [Related]
13. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
Tsai MK; Hu RH; Lee CJ; Lee PH
J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
[TBL] [Abstract][Full Text] [Related]
16. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
[TBL] [Abstract][Full Text] [Related]
17. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
Triemer HL; Pearson TC; Odom KL; Larsen CP
Clin Transplant; 2000 Aug; 14(4 Pt 2):413-20. PubMed ID: 10946781
[TBL] [Abstract][Full Text] [Related]
18. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations.
Kim YS; Moon JI; Kim SI; Park K
Transplantation; 1999 Aug; 68(4):578-81. PubMed ID: 10480420
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial.
Höcker B; Weber LT; Bunchman T; Rashford M; Tönshoff B;
Pediatr Transplant; 2005 Aug; 9(4):504-11. PubMed ID: 16048604
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial.
Sterneck M; Fischer L; Gahlemann C; Gundlach M; Rogiers X; Broelsch C
Ann Transplant; 2000; 5(1):43-6. PubMed ID: 10850611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
